Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inovio Pharmaceuticals

1.85
+0.07003.93%
Post-market: 1.890.0426+2.30%19:59 EDT
Volume:504.83K
Turnover:924.66K
Market Cap:67.83M
PE:-0.47
High:1.86
Open:1.80
Low:1.78
Close:1.78
Loading ...

Inovio Pharma Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)

TIPRANKS
·
19 Mar

RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
19 Mar

Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
19 Mar

JMP Securities Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)

TIPRANKS
·
19 Mar

Inovio Pharmaceuticals Reports 2024 Financial Results

TIPRANKS
·
19 Mar

Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
19 Mar

Inovio Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Inovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate

Benzinga
·
19 Mar

Inovio Pharmaceuticals Inc - on Track to Begin Rolling Submission of Bla in Mid-2025

THOMSON REUTERS
·
19 Mar

Press Release: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dow Jones
·
19 Mar

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Inovio Pharmaceuticals Inc. Stock Rallies 5.2%, Outperforms Competitors

Dow Jones
·
15 Mar

Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
15 Mar

Inovio Pharma Price Target Maintained With a $18.00/Share by Citizens Capital Markets

Dow Jones
·
14 Mar

Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19

MT Newswires Live
·
14 Mar

Promising Developments in Inovio Pharmaceuticals’ DMAb Platform Justify Buy Rating

TIPRANKS
·
14 Mar

Inovio Announces Promising Interim Results From Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (Dmabs) for Covid-19

THOMSON REUTERS
·
14 Mar

Inovio Pharmaceuticals Inc - Dmabs Well-Tolerated With Mild, Temporary Side Effects

THOMSON REUTERS
·
14 Mar